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BACKGROUND: Neuropilin-1 (NRP1) is a non-tyrosine kinase receptor for vascular endothelial growth factor (VEGF) recently
implicated in tumour functions.
METHODS: In this study we used a specific antagonist of VEGF binding to the NRP1 b1 domain, EG3287, to investigate the functional
roles of NRP1 in human carcinoma cell lines, non-small-cell lung A549, kidney ACHN, and prostate DU145 cells expressing NRP1,
and the underlying mechanisms involved.
RESULTS: EG3287 potently displaced the specific binding of VEGF to NRP1 in carcinoma cell lines and significantly inhibited
the migration of A549 and ACHN cells. Neuropilin-1 downregulation by siRNA also decreased cell migration. EG3287 reduced the
adhesion of A549 and ACHN cells to extracellular matrix (ECM), and enhanced the anti-adhesive effects of a b1-integrin function-
blocking antibody. EG3287 increased the cytotoxic effects of the chemotherapeutic agents 5-FU, paclitaxel, or cisplatin on A549 and
DU145 cells, through inhibition of integrin-dependent cell interaction with the ECM.
CONCLUSIONS: These findings indicate that NRP1 is important for tumour cell migration and adhesion, and that NRP1 antagonism
enhances chemosensitivity, at least in part, by interfering with integrin-dependent survival pathways. A major implication of this study
is that therapeutic strategies targeting NRP1 in tumour cells may be particularly useful in combination with other drugs for combating
tumour survival, growth, and metastatic spread independently of an antiangiogenic effect of blocking NRP1.
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Neuropilin-1 (NRP1) is a co-receptor for class-3 semaphorins
in neuronal guidance, and for the angiogenic cytokine vascular
endothelial growth factor (VEGF or VEGF-A) in vascular develop-
ment (Geretti et al, 2008; Pellet-Many et al, 2008; Larrive ´e et al,
2009). Neuropilin-1 requires plexin-A1 to transduce semaphorin-
3A signalling in neuronal cells, which is implicated in chemo-
repulsion and neuronal cell migration (He and Tessier-Lavigne,
1997; Kolodkin et al, 1997; Takahashi et al, 1999; Tamagnone et al,
1999). In endothelial cells, NRP1 enhances VEGFR-2-mediated
VEGF functions, including cell migration and angiogenesis (Soker
et al, 1998; Whitaker et al, 2001; Lee et al, 2002). Neuropilin-1 and
the closely related protein, NRP2, share 44% amino-acid sequence
identity and a common structure comprising a large extracellular
region containing a1/a2 (CUB), b1/b2 (FV/FVIII), and c (MAM)
domains; a transmembrane domain; and a short cytoplasmic
region (Chen et al, 1997; Kolodkin et al, 1997; Fujisawa, 2004). The
a1/a2 and b1/b2 domains of NRP1 form the binding sites of
semaphorin-3A, whereas VEGF binding requires the b1/b2 domain
(Gu et al, 2002; Mamluk et al, 2002). The cytoplasmic domain of
NRP1 consists of 44 amino acids and contains a C-terminal three-
amino-acid PDZ-domain-binding motif, SEA, which binds to the
PDZ domain protein, GAIP-interacting protein, at the C-terminus
(GIPC), also called the neuropinlin-interacting protein (Cai and
Reed, 1999). A naturally truncated and secreted form of soluble
NRP1 splice variant has been identified (Gagnon et al, 2000),
which maintains the binding properties (a and b domains) of
full-length transmembrane NRP1.
Neuropilin-1 and NRP2 are present in various tumour
types from patient specimens and overexpressed NRP1 or both
NRPs correlate with tumour growth, disease progression, and
patient prognosis (Bielenberg et al, 2006; Ellis, 2006; Guttmann-
Raviv et al, 2006). Clinical studies of patients have shown that
NRPl overexpression is positively associated with metastatic
potential, advanced stage, and clinical grade of prostate carcinoma
(Latil et al, 2000). In gastrointestinal carcinomas, increased
expression of NRP1 correlates with the acquisition of invasive
behaviour and metastatic potential (Hansel et al, 2004). Advanced
colorectal carcinoma patients with high levels of NRP1 expression
have shown a higher incidence of lymph node or liver metastasis
and a shorter 5-year survival rate (Ochiumi et al, 2006).
Coexpression of NRP1 and NRP2 also increases in the progres-
sion from dysplasia to microinvasive lung carcinoma, and corre-
lates significantly with tumour progression and poor prognosis
Revised 26 November 2009; accepted 16 December 2009; published
online 19 January 2010
*Correspondence: Dr H Jia or Professor I Zachary, Department of
Medicine, Centre for Cardiovascular Biology and Medicine, and Ark
Therapeutics Limited, The Rayne Building, University College London,
5 University Street, London WC1E 6JJ, UK;
E-mails: haiyan.jia@ucl.ac.uk or i.zachary@ucl.ac.uk
British Journal of Cancer (2010) 102, 541–552
& 2010 Cancer Research UK All rights reserved 0007– 0920/10 $32.00
www.bjcancer.com
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sin patients with non-small-cell lung carcinoma (Kawakami et al,
2002).
Neuropilin-1 and NRP2 are expressed in a wide variety of
human tumour cell lines and implicated in the survival, migration,
and invasion of tumour cells (Bielenberg et al, 2006; Guttmann-
Raviv et al, 2006; Frankel et al, 2008). It has been suggested that
NRP1 predominantly expresses in carcinoma cell lines (epithelial
origin), including carcinomas of lung, breast, prostate, pancreas,
and colon, whereas NRP2 is frequently present in non-carcinoma
cell lines derived from melanoma, leukaemia, and neuroblastoma
(Bielenberg et al, 2006). Studies show that overexpression of NRP1
promotes, while blockade of NRP1 inhibits, tumour cell survival
and migration (Miao et al, 2000; Bachelder et al, 2001, 2003; Barr
et al, 2005; Chabbert-de Ponnat et al, 2006), consistent with a pro-
tumorigenic role of NRP1 and direct contribution to tumour
progression. While some studies point to a direct role of NRP1 in
tumour cell functions, a recent report showed that the ability of
blocking NRP1 antibodies from inhibiting tumour growth in vivo
was not dependent on the tumour cell expression of NRP1, or the
direct anti-tumour effects of NRP1 blockade, but was mediated by
an antiangiogenic effect on the tumour vasculature (Pan et al,
2007). It is therefore unclear whether NRP1 is important for
tumour cell functions relevant for neoplastic growth and
metastatic spread.
We previously characterised a bicyclic peptide, EG3287, based
on the C-terminal NRP1-binding domain of VEGF, which
specifically blocked VEGF binding to NRP1 and inhibited the
anti-chemorepulsive effect of VEGF in dorsal root ganglion
neuronal explants (Cheng et al, 2004) and the biological effects
of VEGF in vascular endothelial cells (Jia et al, 2006). In the
present study, we investigated the effects of EG3287 on the
functions of human carcinoma lung A549, kidney ACHN, and
prostate DU145 cells expressing NRP1 but lacking VEGFR-2, and
the mechanisms underlying these effects.
MATERIALS AND METHODS
Reagents
Recombinant human VEGF (VEGF-A165) was obtained from
R&D Systems (Abingdon, UK). Antibodies against NRP1, NRP2,
VEGFR-1, and VEGFR-2 were purchased from Santa Cruz
Biotechnology Inc. (Heidelberg, Germany). A functional blocking
antibody against the integrin b1-subunit was from Millipore
(Livingston, UK). EG3287 (purity 490%) was synthesised by
Bachem Inc. (Merseyside, UK) as described previously (Cheng
et al, 2004; Jia et al, 2006). Collagen type-I, cell dissociation
solution, Dulbecco’s modified Eagle’s medium (DMEM)/25mM
HEPES, 5-fluorouracil (5-FU), paclitaxel, and cisplatin were
purchased from Sigma-Aldrich (Dorset, UK). All other reagents
used were of the purest grade available.
Cell culture
The human carcinoma cell lines lung A549 and kidney ACHN,
originally from ECACC, were provided by Quintiles Limited
(Edinburgh, UK) and grown in RPMI-1640 medium/L-glutamine
(Invitrogen, Paisley, UK) containing 10% FBS. The human
carcinoma cell lines breast MDA-MB-453 and prostate DU145
were purchased from ATCC (Manassas, VA, USA) and cultured
in DMEM (Invitrogen, Paisley, UK) containing 10% FBS and
RPMI-1640 medium/L-glutamine containing 10% FBS, respec-
tively. Human umbilical vein endothelial cells (HUVECs) were
obtained from TCS CellWorks (Buckingham, UK) and cultured in
EBM (Cambrex BioScience Ltd, Nottingham, UK) supplemented
with human epidermal growth factor, bovine brain extract, and
10% FBS.
Immunoblotting
Cells were extracted using lysis buffer (64mM Tris–HCl (pH 6.8),
0.2mM Na3VO4, 2% SDS, 10% glycerol, protease inhibitors for
serine, cysteine, metalloproteases). The whole-cell lysate samples
were separated by SDS–PAGE and transferred to Immobilon
membranes (Millipore). The membranes were immunoblotted with
specific primary antibodies. Immunoreactive bands were visualised
by chemiluminescence using horseradish peroxidase-conjugated
secondary antibodies and enhanced chemiluminescence reagent
(Amersham Biosciences, Bucks, UK).
125I-VEGF binding
Binding displacement experiments were performed as described
previously (Jia et al, 2006), using carcinoma cells grown to
confluence in 24-well plates and using the indicted concentrations
of EG3287 and 0.1nM of
125I-VEGF-A165 (1200–1800Cimmol
 1;
GE Healthcare, Little Chalfont, Buckinghamshire, UK). Non-
specific binding was determined in the presence of 100-fold excess
unlabelled VEGF.
Cell migration
Cell migration was measured in chemotaxis 24-transwell
plates using collagen-I-coated inserts incorporating polyethylene
terephthalate track-etched membranes with 8-mm pores (Becton
Dickinson Biosciences, Le Pont De Claix, France). Different
concentrations of serum or VEGF in RPMI-1640/0.1% BSA were
placed in the bottom wells of the plates. Cells were trypsinised,
washed, and resuspended in RPMI-1640/0.1% BSA. A total of
1.5 10
6 cells with or without EG3287 treatment, as indicated,
were loaded into each top inserts. The chemotaxis transwell plates
were incubated at 371C for 4h. After the incubation, non-migrated
cells on the top side of the transwell membranes were removed,
and migrated cells on the underside of the transwell membranes
were stained using the REASTAIN Quick-Diff kit (Reagena Ltd,
Toivala, Finland). The stained cells from each well were counted in
four fields at  100 magnification using an eyepiece-indexed
graticule (100 grids).
Cell proliferation
Carcinoma cells were seeded at a density of 2 10
4 cells per well of
24-well plates or at the indicated densities in 0.5ml of RPMI-1640
medium containing 0.5% serum. Five hours after plating, the
medium was replaced with fresh medium containing 5% serum,
25ngml
 1 VEGF, or various concentrations of 5-FU, as indicated,
in the absence or presence of EG3287 at 100mM. After 3 days,
the cell numbers were determined using a Sysmex CDA-500 cell
counter.
Measurement of VEGF
The concentrations of VEGF (VEGF-A165) were determined in the
conditioned media of cell culture using a specific immunoassay kit
(R&D Systems) according to the manufacturer’s instructions.
RNA interference
A 21-mer annealed small interference RNA (siRNA) targeting
human VEGF was obtained from Santa Cruz Biotechnology Inc.
Carcinoma cells were transfected with the VEGF siRNA (sc-29520)
at 10nM using the transfection reagent INTERFERin (Polyplus-
transfection Inc., Illkirch, France) according to the manufacturer’s
instructions. Pre-designed 21-mer annealed siRNAs targeting
human NRP1 or NRP2 were purchased from Ambion Europe
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NRP1 siRNA (ID no. 4820), NRP1 siRNA (ID no. 4914), or NRP2
siRNA (ID no. 107264) at 100nM using the transfection reagent
siPORT NeoFX according to the manufacturer’s instructions. In
parallel, Silencer-negative control #1 siRNA (ID no. 4611), which is
a non-targeting scrambled siRNA, and Silencer GAPDH siRNA
control (ID no. 4605) were used at the same concentration. The
knockdown effects of VEGF, NRP1, or NRP2 siRNA were then
determined by real-time quantitative PCR, immunoassay, immu-
noblotting, and migration assays. Total RNA from transfected cell
was extracted using RNeasy kit (Qiagen Ltd, Crawley, UK) and
treated with DNase-I. Single-stranded cDNA was reverse-tran-
scribed from total RNA with oligo-d(T)16 primer using GeneAmp
kit (Applied Biosystems, Austin, TX, USA). Primers (synthesised
by Sigma Genosys, Gillingham, UK) for real-time PCR were
designed to flank the 30-untranslated region of the gene sequence
to ensure the specificity of the fragment, and to ensure that
amplified fragments were 200–250 base pairs (Supplementary
Table 1). Amplification of predicted fragments was verified by
conventional RT-PCR. Real-time quantitative PCR was performed
using the LightCycler-FastStart DNA Master SYBR Green I kit and
the Lightcycler System (Roche Diagnostics, Lewes, UK), as
previously described (Jia et al, 2004).
Cell–matrix adhesion
Cell adhesion to extracellular matrix (ECM) proteins, including
basement membrane protein complex (BMC), laminin-I, collagen-IV,
or fibronectin, was measured by the Innocyte ECM cell adhesion
assay (Calbiochem Inc., Nottingham, UK). Cells were detached with
a non-enzyme cell dissociation solution, washed, and resuspended
in RPMI-1640 medium. Cells were pretreated with EG3287 or the
function-blocking integrin-b1 antibody at various concentrations as
indicated for 30min and then seeded at a density of 3 10
4 cells per
matrix-coated well in 96-well plates. After 1.5h of incubation the cells
were washed with PBS. The attached cells were labelled with the
green fluorescent dye calcein-AM and measured using a fluorescence
plate reader at an excitation wavelength of 485nm and an emission
wavelength of 510nm.
Cell viability
Cell viability was determined by measuring the conversion of the
tetrazolium salt XTT to form formazan dye. Carcinoma cells were
seeded at a density of 4 10
3 cells per well on non-coated or
fibronectin-coated 96-well plates in 100ml serum-free medium
containing various concentrations of 5-FU, paclitaxel, or cisplatin
as indicated in the absence or presence of EG3287 at 100mM.A f t e r
44h of incubation, the XTT labelling reagent mixture (Roche
Diagnostics, East Sussex, UK) was added to the cultures and they
were incubated for a further 4h. The formazan product was then
measured at A490nm with a reference wavelength at 595nm.
Statistical analysis
Data were analysed using Prism (version 4.0) statistical packages.
Comparisons of two sets of continuous variables were performed
using Student’s t-test or t-test with Welch’s correction where
appropriate. Differences among three or four concentrations of
compounds were evaluated by the one-way analysis of variance
(ANOVA) with Bonferroni’s multiple comparison tests. Differences
between two treatment groups at various concentrations were
analysed using the two-way ANOVA with Bonferroni’s post-tests.
The values represent means±s.e.m. determined from the results of
three independent experiments each performed in duplicates or
triplicates unless where stated. Po0.05 was considered statistically
significant.
RESULTS
Inhibition of
125I-VEGF binding and VEGF-induced
migration in NRP1-expressing lung carcinoma cells by
EG3287
The NRP1 antagonist EG3287 was first tested for its ability to
compete VEGF binding to NRP1-expressing lung carcinoma A549
cells (Supplementary Figure 1). EG3287 displaced the specific
binding of
125I-VEGF to A549 cells with a half-maximal inhibition
(IC50)o f2mM (Figure 1A). Inhibition of
125I-VEGF binding by the
peptide was concentration-dependent and reached a maximum of
100% inhibition at 24mM. The potency and efficacy of the peptide
were very similar to previous results from porcine aortic
endothelial cells expressing NRP1 and human breast carcinoma
MDA-MB-231 cells (Jia et al, 2006).
Since NRP1 has been strongly implicated in the migratory
response to VEGF in endothelial cells (Soker et al, 1998; Whitaker
et al, 2001; Bernatchez et al, 2002; Lee et al, 2002), initially we
examined the effects of EG3287 on tumour cell chemotaxis induced
by VEGF. While A549 cells expressed levels of NRP1 and NRP2
similar to those in endothelial cells, western blotting showed that
A549 cells had no detectable protein expression of the main
signalling receptor for VEGF, VEGFR-2 (Supplementary Figure 1).
Exogenous VEGF at 25ngml
 1 did not increase the migration of
A549 cells through a collagen-coated membrane after 4h of
incubation using a 24-transwell chamber assay (Figure 1B). We
also evaluated whether exogenous VEGF could stimulate carcinoma
cell proliferation. There was no effect on A549 cell proliferation as
determined by counting cell numbers after a 3-day incubation with
VEGF relative to untreated control (Supplementary Figure 2A).
However, carcinoma cells responded well to serum stimulation in
assays of cell migration and growth (Figure 1B and Supplementary
Figure 2A).
Determination of endogenously produced VEGF (VEGF-A165)
levels in the conditioned media of A549 cells by ELISA showed
a significant increase in VEGF after 4h (235pgml
 1) and higher
levels after 48h (1.5ngml
 1) and 72h (2.7ngml
 1) of incubation
(Figure 1C). These results suggested that the effects of exogenously
added VEGF might be masked by secretion of endogenous VEGF.
This was investigated by examining the effect of endogenous VEGF
knockdown using a specific siRNA. As shown in Figure 1D, siRNA
specifically targeted at VEGF markedly reduced VEGF production
as measured by ELISA using cell culture supernatants after
different time periods of cell incubation. We then determined
whether siRNA-mediated endogenous VEGF knockdown modu-
lated the migratory response of tumour cells to exogenous VEGF.
A549 cells in which VEGF gene expression had been inhibited by
siRNA, exhibited increased migration in response to a gradient of
exogenous VEGF (Figure 1E). This enhanced migratory response
to exogenous VEGF was blocked by pretreatment with the NRP1
antagonist, EG3287 (Figure 1F).
We also studied the effects of EG3287 on carcinoma cell
migration in response to serum chemoattraction. Treatment of
A549 cells with EG3287 at various concentrations effectively
reduced serum-induced cell migration in a concentration-
dependent manner (Figure 2A). Compared with untreated control
cells, EG3287 almost abolished the increased cell migration
induced by serum.
To further investigate the role of NRP1 in carcinoma cell
migration, we used RNA interference to knock down NRP1
expression. Transfection of A549 cells with two individual specific
siRNAs targeted against NRP1 mRNA showed effective knockdown
of NRP1 gene expression (by 82%; Supplementary Figure 2B) and
protein expression (Figure 2B and Supplementary Figure 2C),
as compared with control siRNA samples. Lowering NRP1
expression by both NRP1 siRNAs inhibited the migration
of A549 cells by 21 and 31% as compared with that in control
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Specific NRP2-targeted siRNA also decreased the chemotaxis of
A549 cells to a similar extent (Figure 2B and C). Double
knockdown of NRP1 and NRP2 caused greater inhibition of the
migration of A549 cells as compared with single knockdown.
Similar results were found using human kidney carcinoma
ACHN cells, which also express NRP1 but not VEGFR-2
(Supplementary Figure 1). EG3287 potently competed
125I-VEGF
binding to ACHN cells with the same IC50 of 2mM (Supplementary
Figure 3A). The treatment with EG3287 caused dose-dependent
inhibition of ACHN cell chemotaxis towards serum, with a
maximum effect of 450% inhibition (Figure 2D). The migration
of ACHN cells was also reduced by siRNA-mediated knockdown
of either NRP1 or NRP2 gene and protein expression (Supple-
mentary Figure 3B and Figure 2E and F). We verified that
NRP1 siRNA transfection did not affect NRP2 expression and
NRP2 siRNA transfection did not silence NRP1 expression in both
lung A549 and kidney ACHN carcinoma cells (Figure 2B and E).
EG3287 suppressed carcinoma cell adhesion to ECM
proteins
We next evaluated the effects of EG3287 on cell adhesion to ECM
proteins, an important step in cancer cell spread, migration, and
invasion. The adhesion of carcinoma cells was determined by
measuring adhesion to the ECM proteins, BMC, laminin-I,
collagen-IV, and fibronectin. As illustrated in Figure 3A, EG3287
treatment generally decreased the adhesion of lung carcinoma
A549 cells to ECM proteins. Compared with untreated controls,
EG3287 caused a significant and dose-dependent inhibition of
A549 cell adhesion to fibronectin.
Since the integrin b1-subunit mediates specific cell binding to
laminin, collagen, and fibronectin, and has been shown to be a
major integrin receptor expressed in carcinoma cells, we evaluated
whether there was possible cooperation of NRP1 with integrin-b1
in carcinoma cell–matrix adhesion. Figure 3B showed that
disruption of integrin-b1 ligation using a function-blocking
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Figure 1 Inhibition of
125I-VEGF binding to NRP1-expressing carcinoma cells by EG3287 and the effects of VEGF on cell migration. (A) Confluent A549
cells were incubated for 2h at 41C with 0.1nM
125I-VEGF in the presence of the indicated concentrations of EG3287. (B) Carcinoma cells were placed into
the top inserts and either no addition (control, C), 25ngml
 1 VEGF, or 0.5 or 1% FBS was added to the bottom wells of the transwell plates. Chemotaxis of
these cells towards VEGF or serum was determined after 4h of incubation. *Po0.05; **Po0.01 vs control. (C) Vascular endothelial growth factor was
measured by ELISA in the conditioned medium collected from cultured A549 cells at the indicated time points after incubation of cells in serum-free
medium. Values represent means±s.d. of VEGF (pgml
 1). (D) A549 cells were transfected with control (C) or VEGF siRNA and incubated in serum-free
medium for the time periods indicated, after which VEGF was measured in the conditioned medium. (E) A549 cells transfected with control or VEGF siRNA
were placed into the top inserts, either no addition (C) or 25ngml
 1 VEGF was added to the bottom wells of the transwell plates and chemotaxis towards
VEGF was determined after 4h of incubation. ***Po0.001 vs control siRNA. (F) VEGF siRNA-transfected cells were pretreated for 30min with EG3287 at
100mM and chemotaxis towards 25ngml
 1 VEGF was determined after 4h of incubation. *Po0.05 vs VEGF siRNA without EG3287.
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sintegrin-b1 antibody at concentrations of 0.4–2mgml
 1 markedly
reduced the adhesion of A549 cells to matrix proteins, but had little
effect at lower concentrations. In the presence of EG3287, the
inhibition of A549 cell adhesion to collagen-IV and fibronectin was
significantly potentiated with the integrin antibody at concentra-
tions of 16 and 80ngml
 1.
In renal carcinoma ACHN cells, similar inhibitory effects of
EG3287 on matrix adhesion were observed (Figure 3C). EG3287
also significantly potentiated the inhibition of ACHN cell adhesion
to laminin-I and fibronectin by the integrin antibody at lower
concentrations (Figure 3D).
Effects of EG3287 on cell growth, survival, and response to
chemotherapeutic agents
The anticancer potential of the NRP1 antagonist was further
investigated by determining the effects of NRP1 antagonism on
the response of carcinoma cells to a chemotherapeutic agent,
5-fluouracil (5-FU), which possesses a broad spectrum of
therapeutic activity against various cancers, including non-small-
cell lung cancer. Treatment of lung carcinoma A549 cells with 5-FU
for 3 days caused a dose-dependent inhibition of cell proliferation
(Figure 4A). As compared with untreated controls, treatment of
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Figure 2 Inhibition of migration of carcinoma cells by EG3287 and NRP1 silencing. (A, D) A549 and ACHN cells were pretreated for 30min with the
indicated concentrations of EG3287 and chemotaxis towards 0, 0.5, or 1% FBS was determined after 4h of incubation. *Po0.05; **Po0.01; and
***Po0.001 vs untreated control. (B, E) A549 and ACHN cells were transfected with NeoFX only as a mock control (M) or siRNAs, as indicated, and total
cellular protein was extracted 48h after transfection, and NRP1 and NRP2 were detected by immunobloting. GAPDH served as loading control. (C, F)
siRNA-transfected A549 and ACHN cells were loaded into the top inserts of transwell plates and chemotaxis towards 0, 0.5, or 1% FBS was determined
after 4h of incubation. *Po0.05 vs control siRNA.
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 1 suppressed cell proliferation by
32%. Treatment with 25ngml
 1 5-FU in combination with 100mM
EG3287 caused a further significant reduction (58%) in the number
of proliferating cells (Po0.01 vs 5-FU alone). However, kidney
carcinoma ACHN cells responded poorly to treatment with 5-FU at
lower concentrations and the combined treatment with 5-FU and
EG3287 had no greater effect on cell proliferation compared with
the single agent 5-FU (Supplementary Figure 3C). Human prostate
carcinoma DU145 cells, which express NRP1 but not VEGFR-2
(Supplementary Figure 1), were then used to examine cell growth
in response to chemotherapy. Similar to A549 cells, the inhibitory
effects on the proliferation of DU145 cells were enhanced by
treatment with 5-FU and EG3287 together (Figure 4B). EG3287
alone had no inhibitory effects on cell proliferation stimulated
by serum.
The effect of EG3287 on 5-FU cytotoxicity was next assessed
using the XTT assay of carcinoma cell viability. Treatment with
5-FU for 2 days induced a decrease in the viability of lung
carcinoma A549 cells in a concentration-dependent manner, with
an IC50 of 53mM (Figure 4C). In the presence of EG3287, 5-FU
showed a 43-fold increase in its potency in reducing cell viability,
with an IC50 of 14mM. In DU145 cells, 5-FU combined with EG3287
showed a similar (43-fold) increase in cytotoxic potency
(Figure 4D), although DU145 cells responded to the drug with an
IC50 of 138mM, compared with 53mM in A549 cells. Interestingly,
EG3287 alone at 100mM modestly reduced the survival of both
lung A549 and prostate DU145 carcinoma cells in the absence of
serum. In contrast, EG3287 caused no alterations in the cytotoxic
effects of 5-FU in breast carcinoma MDA-MB-453 cells, which are
NRP1-negative (Figure 4E).
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Figure 3 Suppression of cell–matrix adhesion and enhancement of the inhibitory effects of an integrin-b1-function-blocking antibody by EG3287. (A, C)
A549 and ACHN cells were pretreated for 30min with the indicated concentrations of EG3287 and seeded to wells coated with the indicated matrix
proteins. After 90min of incubation, attached cells were labelled with calcein-AM and measured using a fluorescence plate reader. *Po0.05; **Po0.01 vs
untreated control. (B, D) A549 and ACHN cells were pretreated for 30min with an integrin-b1-blocking antibody at the indicated concentrations in
the absence or presence of 100mM EG3287, and cell adhesion to matrix proteins was measured. *Po0.05; **Po0.01 for integrin-b1 antibody alone vs
integrin-b1 antibody plus EG3287.
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different classes of chemotherapeutic agents clinically used as
frontline treatment for advanced non-small-cell lung cancer and
prostate cancer, respectively. As shown in Figure 4F, the cytotoxic
activity of paclitaxel on lung carcinoma A549 cells was dose-
dependent and exhibited greater potency than 5-FU. The
combination of paclitaxel and EG3287 caused a further decrease
in cell viability (IC50¼0.2mM) as compared with treatment with
paclitaxel alone (IC50¼0.4mM). Consistently, EG3287 increased the
cytotoxic activity of cisplatin in prostate carcinoma DU145 cells
with an improved IC50 of 28mM (Figure 4G). The involvement of
NRP1 in carcinoma cell survival and drug response was also
examined by downregulation of NRP1 expression. In agreement
with NRP1 antagonism, NRP1 silencing with two individual
specific siRNAs in lung carcinoma A549 cells decreased cell
viability and increased the cytotoxic effects of both 5-FU and
paclitaxel as compared with that in control siRNA-transfected cells
(Figure 4H).
EG3287 decreased fibronectin-mediated cell viability and
chemoresistance
Since adhesion of cancer cells to ECM is associated with increased
resistance to several cytotoxic drugs (Broxterman et al, 2003), we
next examined the response to the chemotherapeutic drug and
EG3287 of A549 cells grown on either fibronectin-coated or non-
coated plates. As shown in Figure 5A, the presence of fibronectin
increased the number of viable cells as compared with non-coated
controls. Fibronectin also increased cell viability in the presence of
5-FU or paclitaxel at concentrations of 0.025–0.25mgml
 1,a s
compared with uncoated controls (Figure 5B and C). However, in
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significantly decreased cell viability (Figure 5A), and fibronectin-
dependent cell survival in the presence of 5-FU or paclitaxel was
abolished by EG3287 treatment (Figure 5B and C).
In prostate carcinoma DU145 cells, a similar increase in cell
viability was found in the presence of fibronectin as compared
with non-coated controls (Figure 6A). The cytotoxic effects of
5-FU or cisplatin at concentrations of 0.025–2.5mgml
 1 were also
reduced in the presence of fibronectin (Figure 6B and C).
Treatment of DU145 cells with EG3287 significantly prevented
fibronectin-mediated cell survival (Figure 6A) and blocked the
fibronectin-dependent cell resistance to 5-FU or cisplatin (Figure
6B and C).
DISCUSSION
In the present study, we investigated the effects of the NRP1
antagonist EG3287 on cell proliferation, survival, migration, and
adhesion to matrix in the NRP1-expressing carcinoma cell lines,
non-small-cell lung A549, kidney ACHN, and prostate DU145 cells.
A major conclusion of this study is that the NRP1 antagonist
EG3287 markedly inhibits the chemotactic migration of carcinoma
lung A549 and kidney ACHN cells. Other studies have examined
the roles of NRP1 in tumour cell survival and proliferation
(Bachelder et al, 2001; Barr et al, 2005; Chabbert-de Ponnat et al,
2006), but the role of NRP1 in tumour cell migration is less well
understood. In the present study, we have shown that the NRP1
antagonist EG3287 significantly inhibited the migration of NRP1-
positive lung carcinoma A549 cells in response to VEGF and
serum. Small interference RNA-mediated inhibition of NRP1
expression also reduced the migration of both A549 and ACHN
cells. Since migration of tumour cells plays a key role in neoplastic
spread, invasion of surrounding tissue, and formation of
metastasis, these findings indicate a key role for NRP1 in the
motility of carcinoma cells, which may contribute to tumour
progression and metastatic potential.
Our results indicate that an important mechanism through
which NRP1 antagonism may inhibit tumour cell migration is
by reducing cell adhesion to ECM. Neuropilin-1 functioned as a
cell–cell adhesion molecule when overexpressed in a mouse fibro-
blast cell line (Takagi et al, 1995), and the b1 and b2 domains of
the NRP1 extracellular domain are essential for cell aggregation
activity independent of VEGF or semaphorin ligands (Shimizu
et al, 2000). However, the cell–matrix adhesive properties of NRP1
have not been investigated previously in carcinoma cells expres-
sing endogenous NRP1. EG3287 reduced the adhesion of both lung
A549 and kidney ACHN carcinoma cells to ECM, suggesting an
important role of NRP1 as a regulator, at least in part, of carci-
noma cell attachment to ECM. Furthermore, NRP1 antagonism
enhanced the inhibitory effect of function-blocking integrin-b1
antibody on carcinoma cell adhesion to ECM, indicating that
NRP1 synergistically cooperates with integrin-b1 to promote
carcinoma cell adhesion to matrix proteins. Since EG3287 had
no significant effect on the cell expression of integrin-b1 (data not
shown), the inhibitory effects of the NRP1 antagonist on
carcinoma cell responses, including adhesion and migration, were
unlikely to have been mediated through downregulation of
integrin-b1 expression. Fukasawa et al (2007) recently reported
an association between NRP1 and integrin-b1 subunit in PANC-1
pancreatic cancer cells. Our data are the first to show a functional
interaction of NRP1 with integrin-b1 in cell–matrix adhesion.
Such an interaction may contribute to integrin and growth factor
receptor crosstalk found in some cell types (Byzova et al, 2000;
Eliceiri, 2001; Streuli and Akhtar, 2009). For example, stimulation
of proliferation of epithelial cells and fibroblasts with epidermal
growth factor depends on b1-integrins, whereas VEGF-promoted
adhesion and migration of endothelial cells are mediated via
integrin-b1, avb3, and avb5. Our findings implicate a role for
NRP1 in promoting integrin-mediated cancer cell attachment and
migration into ECM.
A549 and ACHN carcinoma cells also expressed NRP2 at a level
similar to that of NRP1. Furthermore, NRP2 siRNA also decreased
tumour cell migration, and combined transfection with NRP1 and
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sNRP2 siRNAs had a greater effect. While a role for NRP1 in VEGF-
dependent cell migration in endothelial cells is well-established,
the role of NRP2 in cell migration has previously not been much
investigated, although VEGF-A165 is known to bind with high
affinity to NRP2. Our results indicate that NRP2 plays a role in the
migration of A549 and ACHN carcinoma cells, and further studies
aimed at investigating the possible cooperation and interaction
between NRP1 and NRP2 would be of interest.
Another important finding of our study is that the NRP1
antagonist sensitised carcinoma cells to the clinically important
chemotherapeutic agents 5-FU, paclitaxel, and cisplatin. The
results showed that EG3287-treated lung A549 and prostate
DU145 cells were more susceptible to the cytotoxic effects of
5-FU, paclitaxel, and cisplatin at suboptimal concentrations as
compared with the chemotherapeutic agents administered alone.
Similarly, downregulation of NRP1 by siRNAs in A549 cells
sensitised the cell response to the chemotherapeutic agents. The
notion that NRP1 may play a role in mediating chemoresistance is
supported by the finding that overexpression of NRP1 promotes
chemoresistance in human FG pancreatic cancer cells (Wey et al,
2005). Our finding that EG3287 combined with chemotherapy
in lung A549 and prostate DU145 cells prevented fibronectin-
dependent chemoresistance, indicates that the mechanism
underlying NRP1-mediated chemoresistance is mediated in part
through the integrin-dependent interaction of carcinoma cells with
the ECM. Interestingly, it has shown that adhesion of leukaemia
cells to fibronectin via integrin-b1 contributes to cell adhesion-
mediated drug resistance (Hazlehurst et al, 2007). Although we
found a modest anti-survival effect of EG3287 on carcinoma A549
and DU145 cells in serum-free medium, we were unable to observe
any growth-inhibitory effects of EG3287 alone on carcinoma cells
in response to serum stimulation, which suggests that NRP1 plays
a less important role in proliferation of these cells. Consistent with
our observations, overexpression of NRP1 increased motility in
colon and prostate carcinoma cells, but had no effect on cell
mitogenesis and proliferation (Miao et al, 2000; Ochiumi et al,
2006).
Several previous investigations of the role of NRP1 in tumour
cells have shown NRP1 as a functional VEGF receptor. Thus, NRP1
mediates the chemotaxis and survival of VEGF autocrine functions
in breast carcinoma MDA-MB-231 cells lacking VEGFR-2
(Bachelder et al, 2001, 2003), and in Dunning rat prostate
carcinoma AT2.1 cells, which do not express VEGFR-2, NRP1
overexpression increases cell migration and reduces cell apoptosis
in vivo (Miao et al, 2000). Since lung carcinoma A549 cells
expressed no detectable VEGFR-2, the chemotactic migration of
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Figure 5 Effects of EG3287 on A549 cell survival in the presence of chemotherapeutic drugs and fibronectin. (A) A549 cells were seeded on non-coated
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scarcinoma cells was highly unlikely to be mediated via VEGFR-2.
These and other findings pose the problem of the mechanism
through which VEGF acts in tumour cells, since the present study
together with previous work shows that NRP1 is expressed in
diverse tumour cells in the absence of significant expression of
the major signalling VEGF receptor, VEGFR-2 (Soker et al, 1998;
Bachelder et al, 2003; Simiantonaki et al, 2008). The possibilities
are that NRP1 mediates tumour cell functions either in a VEGF-
dependent manner, but independent of VEGFR-2 signalling, or
via interaction with other cell-surface receptors and ligands,
to transduce signalling and biological functions. A recent paper
describing the effects of NRP1 antibodies that specifically block
VEGF binding to the b1/b2 domain, concluded that the effects of
NRP1 inhibition on endothelial cell function and angiogenesis
appeared to be partly independent of VEGF, and also reported no
effects of blocking NRP1 antibodies on tumour cell proliferation,
but did not examine the effects on tumour cell migration and
adhesion (Pan et al, 2007). Many tumour cells produce high levels
of VEGF, which may block the effects of exogenous VEGF by
saturating and/or downregulating surface receptors. In the present
paper, while treatment of NRP1-expressing carcinoma cells with
exogenous VEGF had no effects on growth and migration, the
effects of VEGF on migration in A549 cells were unmasked by
siRNA-mediated inhibition of endogenous VEGF production, most
likely because endogenous VEGF production limits the formation
of a chemoattractant gradient. Overall, we conclude that the
inhibitory effects of the NRP1 antagonist, EG3287, on A549 cell
migration and adhesion are mediated via a VEGF-dependent but
VEGR-2-independent mechanism. Interestingly, the hepatocyte
growth factor (HGF) has been identified recently as an additional
ligand for NRP1, which potentiated HGF/c-Met signalling and
promoted glioma progression and pancreatic cancer cell invasion
(Hu et al, 2007; Matsushita et al, 2007). It is possible, therefore,
that NRP1 antagonists and siRNAs could indirectly affect tumour
cell function by impairing functional signalling mediated via other
receptors such as c-Met. Understanding the molecular basis for the
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Figure 6 Effects of EG3287 on DU145 cell survival in the presence of chemotherapeutic drugs and fibronectin. (A) DU145 cells were seeded on
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schemotactic effects of VEGF in VEGFR-2-negative tumour cells,
and the role played by NRP1, warrant further work.
There is increasing evidence that NRP1 plays a direct role in
tumour cell biology and becomes an attractive target for anticancer
strategy. The present study suggests that peptide antagonists of
NRP1 may be therapeutically useful for preventing tumour cell
functions required for metastasis and tumour spread. In addition,
the finding that EG3287 sensitises carcinoma cells to paclitaxel,
5-FU, and cisplatin is of interest since most chemotherapeutic
agents have limited efficacy and unwanted side effects, and raises
the possibility that NRP1 antagonism may have anticancer
potential in combination with conventional chemotherapeutics.
Theoretically, combinations of conventional chemotherapy with
targeted biological therapy for specific patients are especially
appealing because such approaches may improve clinical efficacy
with minimal adverse events.
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